Document is current
Any future updates will be listed below
-
Authors
Gladman, Dafna D. http://orcid.org/0000-0002-9074-0592
Coates, Laura C.
Wu, Joseph
Fallon, Lara
Bacci, Elizabeth D.
Cappelleri, Joseph C.
Bushmakin, Andrew G.
Helliwell, Philip S.
-
Funding
Funding for this research was provided by:
Pfizer Inc
- License Information
-
More Information
Article History
Received: 10 November 2021
Accepted: 13 January 2022
First Online: 9 February 2022
Declarations
:
: OPAL Broaden and OPAL Beyond were conducted in accordance with the Good Clinical Practice Guidelines of the International Conference on Harmonization and with the principles of the Declaration of Helsinki. All patients provided written informed consent.
: Not applicable
: DDG has received research grants from AbbVie, Amgen, Celgene, Eli Lilly, Novartis, Pfizer Inc, and UCB, and has been a consultant for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Galapagos, Gilead, Eli Lilly, Janssen, Novartis, Pfizer Inc, and UCB. LCC has received research grants from AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Novartis, Pfizer Inc, and UCB, has acted as a consultant for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer Inc, and UCB, and has received honoraria from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, GSK, Janssen, Lilly, Medac, Novartis, Pfizer Inc, and UCB. JW, LF, JCC, and AGB are employees and stockholders of Pfizer Inc. EDB has received consulting fees from Pfizer Inc. PSH has received research grants from AbbVie, Janssen, and Novartis, and has received honoraria from AbbVie, Amgen, Celgene, Galapagos, Pfizer Inc, and UCB.
